07:50 EDT Merus (MRUS) up 38% at $94.82 after Genmab acquisition announcement at $97 per share
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Genmab acquires Merus for $97 per share in cash or $8B
- Genmab near deal to acquire Merus, Bloomberg says
- Merus initiated with an Overweight at Barclays
- Merus’s Oncology Potential and Financial Stability Justify Buy Rating
- Merus N.V.’s Phase 3 Study on Petosemtamab: A Potential Game-Changer for Head and Neck Cancer